Tarsier Pharma

Executive Summary

Tarsier Pharma is a private Israeli late-stage biotech developing Dazdotuftide (TRS), a bio-inspired immunomodulatory platform designed to provide safer, more effective alternatives to corticosteroids for autoimmune and inflammatory ocular diseases. Its lead candidate targets non-infectious uveitis via both eye-drop and intravitreal formulations, addressing a significant unmet need where chronic steroid use leads to serious side effects. The company has advanced to Phase 2 clinical development, leveraging its unique mechanism to modulate immune responses locally in the eye. With a strong scientific foundation and a focused pipeline, Tarsier Pharma is positioned to capture a share of the multi-billion-dollar ophthalmic immunology market. However, as a private firm with limited disclosed funding data, near-term financial visibility is constrained, and clinical execution risks remain. The upcoming Phase 2 readout will be a critical milestone; if positive, it could unlock partnership opportunities and accelerate development toward registration.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 top-line data for TRS in non-infectious uveitis40% success
• H1 2026Regulatory feedback or IND update for new formulation/indication70% success
• H2 2026Strategic partnership or licensing deal for ex-Israel rights30% success